NEW YORK (GenomeWeb News) – The United Kingdom's National Institute of Health Research will work with GeneGo in a collaboration that the company hopes will lead to development of a pathway analysis tool for the central nervous system.
GeneGo said it is working with NIHR's Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and King's College London through its MetaMiner CNS Partnership Program.
The program involves developing a series of blueprint CNS disease pathway maps for schizophrenia, Alzheimer's and Huntington's diseases, collecting experimental data from the public domain, and making it available for analysis.
"Currently there is a huge amount of CNS data available but until now no one has brought it all together in a comprehensive form," BRC Director Simon Lovestone said in a statement.
"Accurate and comprehensive pathway annotation is necessary for us to discern the biological mechanisms revealed by large scale 'omics approaches to CNS disorders, such as genomewide association and expression array studies," BRC-MH Genetics Coordinator Gerome Breen added.